Talphera, Inc. (NASDAQ:TLPH) Short Interest Down 51.1% in November

Talphera, Inc. (NASDAQ:TLPH) was the recipient of a significant drop in short interest during the month of November. As of November 30th, there was short interest totalling 41,900 shares, a drop of 51.1% from the November 15th total of 85,600 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average trading volume of 99,700 shares, the short-interest ratio is currently 0.4 days.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Talphera in a report on Friday, August 16th. Maxim Group upgraded Talphera to a “strong-buy” rating in a report on Friday, November 8th.

Hedge Funds Weigh In On Talphera

A number of hedge funds and other institutional investors have recently made changes to their positions in TLPH. Nantahala Capital Management LLC bought a new position in Talphera during the 2nd quarter worth about $1,773,000. Rosalind Advisors Inc. bought a new position in shares of Talphera during the third quarter worth about $650,000. Finally, Turtle Creek Wealth Advisors LLC acquired a new stake in Talphera in the 2nd quarter valued at approximately $64,000. 37.67% of the stock is owned by institutional investors.

Talphera Trading Down 1.1 %

NASDAQ TLPH traded down $0.01 during trading hours on Friday, reaching $0.65. 62,975 shares of the company’s stock were exchanged, compared to its average volume of 91,149. The firm has a fifty day moving average of $0.82 and a 200-day moving average of $0.89. Talphera has a one year low of $0.62 and a one year high of $1.61. The stock has a market cap of $11.07 million, a PE ratio of -0.94 and a beta of 0.25.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.